| Revenue growth | 8% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin expanded from 13.3% (FY25) to 16.6% (FY26). |
| Demand visibility | Strong pipeline with 4 new API launches per year. |
| Management confidence | High; citing improved plant utilization and yields. |
Growth
FY26 Revenue grew 8% to ₹650 Cr; EBITDA rose 35% to ₹108 Cr; PAT jumped 117% to ₹66 Cr.
Outlook
Launching 4 new molecules annually from FY27; targeting formulation scale-up and further debt refinancing.
Risks
Q4 revenue declined due to the West Asia crisis impacting API export dispatches in March.
Earnings Call filed with NSE, NSE: WANBURY. Summary written with AI assistance from the document.
Wanbury Ltd: key numbers
- Share price
- ₹201.31
- Market cap
- ₹703.9 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.6×Sector 47.4×
- Promoter holding
- 43.02%+0.00% QoQ
- FII holding
- 0.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wanbury Ltd
All →Wanbury Management Change
Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.
Wanbury Annual General Meeting
Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.
Wanbury Annual General Meeting
Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.
- Value
- ₹0.04 Cr
Wanbury Annual General Meeting
Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.
Wanbury Product Launch
Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.
Wanbury Results Update
Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.
- Value
- ₹205.0 Cr